Last updated: 11/06/2018 23:40:59
An open follow-up of patients in Studies 056 and 125 for up to 10 years (No study medication provided).
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An open follow-up of patients in Studies 056 and 125 for up to 10 years (No study medication provided).
Trial description: An open follow-up of patients in Studies 056 and 125 for up to 10 years (No study medication provided).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
5-year follow-up REAL-PET study in patients with early Parkinson’s disease (PD) initially receiving ropinirole or l-dopa R Watts, A Lang, O Rascol, W Poewe, J Stoessl, R Hauser 9th International Congress of Parkinson’s Disease and Movement Disorders, New Orleans, USA, 5–8 March 2005 Mov Disord 2005; 20(Suppl 10): S133
An 8.5-year follow-up of patients with early Parkinson’s disease initially receiving ropinirole or l-dopa. Rascol O, De Deyn PP, Watts RL, Korczyn AD, Lang AE European Federation of Neurological Societies, Helsinki, Finland, Aug 30–Sep 2 2003 Eur J Neurol 2003; 10(suppl 1): 18: SC201
Incidence of Dyskinesia in a 10-yr Follow-Up of Patients with Early Parkinson's Disease (PD) Initially Receiving Ropinirole Compared with L-dopa Amos D. Korczyn, Tel Aviv, Israel, Peter P. De Deyn, Antwerp, Belgium, Olivier Rascol, Toulouse, France, Anthony Lang, Toronto, ON, Canada American Academy of Neurology, Miami Beach, USA, 9–16 Apr 2005
Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson’s disease (PD) initially receiving ropinirole compared with l –dopa O Rascol, AD Korczyn, P De Deyn, A Lang 9th International Congress of Parkinson’s Disease and Movement Disorders, New Orleans, USA, 5–8 March 2005
Reduced dyskinesia with ropinirole in a naturalistic, 8.5-year follow-up of patients with early Parkinson’s disease (PD) who had initially received ropinirole or l-dopa Rascol O, De Deyn PP, Watts RL, Korczyn AD, AE Lang, on behalf of the 170 Study Group International Congress of Parkinson’s Disease and Movement Disorders, Rome, Italy, Jun 13–17 2004 Mov Disord 2004; 19(suppl 9): S253: P722
Medical condition
Parkinson Disease
Product
ropinirole
Collaborators
Not applicable
Study date(s)
June 2000 to April 2004
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2004-13-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website